Dr. Thompson on Advancements in Treatments of Multiple Myeloma

Video

In Partnership With:

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

In the field of multiple myeloma, many drugs received FDA approval in 2016. The next important steps are to discover effective ways to use those drugs, Thompson explains. One of the most promising drugs in the field of multiple myeloma is daratumumab (Darzalex). There is now more data looking at different populations of patients treated for longer lengths of time and it still appears beneficial.

Some researchers are looking at combinations of elotuzumab (Empliciti) with checkpoint inhibitors, Thompson says. Other noteworthy drugs in this field are ixazomib (Ninlaro), selinixor, and venetoclax (Venclexta).

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,